<DOC>
	<DOCNO>NCT00514722</DOCNO>
	<brief_summary>This pilot study design evaluate safety feasibility perform umbilical cord blood transplant adult high-risk hematopoietic malignancy . A novel myeloablative preparative regimen use . One , maximum three cord blood unit administer facilitate engraftment .</brief_summary>
	<brief_title>Pilot Study Umbilical Cord Blood Transplantation Adult Patient With Advanced Hematopoietic Malignancies</brief_title>
	<detailed_description>This study intend demonstrate engraftment rate &gt; 80 % day 100 post-transplantation transplant relate mortality rate &lt; equal 50 % . A TRM &gt; 50 % consider unacceptable . The present research also : - Evaluate toxicity busulfan , fludarabine , etoposide preparative therapy prior umbilical cord blood cell transplantation . - Evaluate neutrophil platelet recovery follow UCB transplantation . - Evaluate lineage-specific chimerism follow transplantation assess contribution individual CB unit post-transplantation hematopoiesis . - Evaluate event free overall survival . - Evaluate incidence , severity time acute chronic GVHD follow UCB transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Age &lt; equal 55 Availability donor cord blood ( one three unit ) match least 4 6 HLA antigen ( A , B , DR ) . HLA class I antigens determined serologic method , Class II antigen determine highresolution DNA typing . Typing confirm UCSF Immunogenetics Department follow infusion . The UCB unit must contain &gt; 2.5 x 10 ( 7 ) TNC per kilogram recipient body weight . Cord blood unit obtain available international bank . HLA identical 1 antigen mismatch related donor potential HLAmatched unrelated donor ( MUD ) match &gt; 6/8 ( A , B , C , DR ) alleles must NOT available . Disease type : Acute myeloid leukemia expect curable chemotherapy . This include patient highrisk cytogenetics ( 7 , 7q , 5 , 5q , ( 6,9 ) , ( 9,11 ) , complex , Ph+ ) , evolution prior myelodysplasia AML secondary prior chemotherapy , failure achieve remission , second subsequent remission . To ensure adequate time disease progression , marrow blast must &lt; equal 10 % . This may achieve use chemotherapy treatment . Myelodysplasia highrisk feature . This include patient IPSS category INT2 HIrisk MDS . Marrow blast must &lt; equal 20 % . If require , chemotherapy may give achieve target level blast . Acute lymphoblastic leukemia expect curable chemotherapy . This include patient highrisk cytogenetics ( Ph+ , ( 4,11 ) , 11q23 abnormality , monosomy 7 ) , patient require one induction course achieve remission , well patient fail enter remission second subsequent remission . To ensure adequate time disease progression , marrow blast must &lt; equal 10 % . If require , chemotherapy may give achieve target level blast . Chronic myelogenous leukemia advance disease . This include patient accelerate blastic phase patient chronic phase refractory STI5741 . To ensure adequate time disease progression , patient blast crisis must show marrow blast &lt; equal 10 % . If require , chemotherapy may give achieve target level blast . Multiple myeloma , stage IIIII &gt; 1st relapse refractory disease newly diagnose chromosome 13 abnormality . Lymphoma : diffuse large cell , mantle cell , peripheral Tcell , TNK cell , Hodgkin 's disease fail respond primary therapy , progress recur prior therapy . Patients fail autologous transplant eligible &gt; 1 year posttransplant . Patients must ECOG PS &lt; equal 2 Laboratory requirement : Creatinine &lt; 2.0mg/dL creatinine clearance &gt; 40/m/min ( calculate base 24 hour urine collection ) Bilirubin &lt; 2.0 mg/dL , AST/alkaline phosphatase &lt; 3x upper limit normal Patients hepatitis C active Hepatitis B eligible liver biopsy perform &lt; equal grade 2 inflammation fibrosis . Cardiac ejection fraction &gt; 40 % DLCO &gt; 40 % Negative pregnancy test ( female reproductive age ) Active infection require ongoing antibiotic treatment HIV infection Poor performance status ( ECOG &gt; 2 ) Rapid progression malignant disease Opinion BMT Committee autologous transplant would preferable form treatment Organ function requirement Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hematopoietic malignancy</keyword>
	<keyword>Umbilical cord blood transplantation</keyword>
	<keyword>Lymphoma : diffuse large cell , mantle cell , peripheral T-cell , T-NK cell , Hodgkin 's</keyword>
</DOC>